ClinicalTrials.gg
CompletedNCT02412878ARROWUpdated Sep 23, 2022Results posted

Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma

A Phase 3 interventional study of Carfilzomib and Dexamethasone in Multiple Myeloma, sponsored by Amgen. Completed at 140 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-23.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
478
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.

Enrollment
6th of 113
478 · median 54
Started
2015
with 1 other
Phase 3
15 of 113
1 open now
Registered
55th of 113
by date
Lead sponsor
21 of 113
Amgen

Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 6th largest by enrollment, is one of 2 that started in 2015, is one of 15 in phase 3, and was the 55th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carfilzomib

carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing carfilzomib in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of the study is to compare the progression-free survival (PFS) of once-weekly carfilzomib dosing in combination with dexamethasone to twice-weekly carfilzomib dosing in combination with dexamethasone in adults with relapsed and refractory multiple myeloma, previously treated with bortezomib and an immunomodulatory agent (IMiD).

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. multiple myeloma
  2. Refractory multiple myeloma defined as meeting 1 or more of the following:

    • Nonresponsive to most recent therapy (stable disease only or PD while on treatment), or
    • Disease progression within 60 days of discontinuation from most recent therapy
  3. At least 2 but no more than 3 prior therapies for multiple myeloma
  4. Prior exposure to an immunomodulatory agent (IMiD)
  5. Prior exposure to a proteasome inhibitor (PI)
  6. Documented response of at least partial response (PR) to 1
  7. with at least 1 of the following assessed within the 21 days prior to randomization:

    • Serum M-protein ≥ 0.5 g/dL
    • Urine M-protein ≥ 200 mg/24 hours
    • In subjects without detectable serum or urine M-protein, serum free light chain (SFLC) > 100 mg/L (involved light chain) and an abnormal serum kappa lambda ratio
  8. Performance Status (ECOG PS) of 0 or 1
  9. (LVEF) ≥ 40% within the 21 days prior to randomization
  10. Adequate organ and bone marrow function within the 21 days prior to randomization defined by:

    • \< 1.5 times the (ULN)
    • (AST) and alanine aminotransferase (ALT) \< 3 times the ULN
    • (ANC) ≥ 1000/mm³ (screening ANC should be independent of growth factor support for ≥ 1 week)
    • ≥ 8.0 g/dL (Use of erythropoietic stimulating factors and red blood cell [RBC] transfusion per institutional guidelines is allowed, however the most recent RBC transfusion may not have been done within 7 days prior to obtaining screening hemoglobin.)
    • count ≥ 50,000/mm³ (≥ 30,000/mm³ if myeloma involvement in the bone marrow is > 50%. Subjects should not have received platelet transfusions for at least 1 week prior to obtaining the screening platelet count.)
    • Calculated or measured (CrCl) of ≥ 30 mL/min

Key Exclusion Criteria:

  1. Waldenström macroglobulinemia
  2. Multiple myeloma of Immunoglobin M (IgM) subtype
  3. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
  4. Plasma cell leukemia (> 2.0 × 10⁹/L circulating plasma cells by standard differential)
  5. Myelodysplastic syndrome
  6. Second within the past 5 years except:

    • Adequately treated basal cell or squamous cell skin cancer
    • Carcinoma in situ of the cervix
    • Prostate cancer \< Gleason score 6 with stable prostate-specific antigen (PSA) over 12 months
    • Ductal breast carcinoma in situ with full surgical resection (i.e., negative margins)
    • Treated medullary or papillary thyroid cancer
    • Similar condition with an expectation of > 95% five-year disease-free survival
  7. History of or current amyloidosis
  8. Cytotoxic chemotherapy within the 28 days prior to randomization
  9. Immunotherapy within the 21 days prior to randomization
  10. therapy within the 14 days prior to randomization that exceeds a cumulative dose of 160 mg of dexamethasone or 1000 mg prednisone
  11. Radiation therapy:

    • Focal therapy within the 7 days prior to randomization
    • Extended field therapy within the 21 days prior to randomization
  12. Prior treatment with either carfilzomib or oprozomib
  13. Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
  14. to dexamethasone or any of the required concomitant drugs or supportive treatments, including to antiviral drugs, or intolerance to hydration due to pre-existing pulmonary or cardiac impairment
  15. Active congestive heart failure ( [NYHA] Class III or IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, acute diffuse infiltrative pulmonary disease, pericardial disease, or myocardial infarction within 6 months prior to enrollment
  16. Active infection within the 14 days prior to randomization requiring systemic antibiotics
  17. Pleural effusions requiring thoracentesis within the 14 days prior to randomization
  18. Ascites requiring paracentesis within the 14 days prior to randomization
  19. Ongoing
  20. Uncontrolled hypertension or uncontrolled diabetes despite medication
  21. Significant neuropathy (≥ Grade 3) within the 14 days prior to randomization
  22. Known cirrhosis
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
478 participants (actual)

Study arms

  • Experimental
    Once-weekly Carfilzomib 20/70 mg/m² + Dexamethasone

    Participants received carfilzomib administered by intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle (20 mg/m² on day 1 of cycle 1 and 70 mg/m² thereafter). Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15.

    Drug: Carfilzomib · Drug: Dexamethasone

  • Experimental
    Twice-weekly Carfilzomib 20/27 mg/m² + Dexamethasone

    Participants received carfilzomib administered by IV infusion on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle (20 mg/m² on days 1 and 2 of cycle 1 and 27 mg/m² thereafter). Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15.

    Drug: Carfilzomib · Drug: Dexamethasone

Interventions

  • Carfilzomib was administered as an IV infusion

    Also known as: PR-171, PR171, Kyprolis® (carfilzomib) for Injection

  • Commercially available dexamethasone was obtained by the investigational site.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival

    Progression-free survival (PFS) was defined as the time from randomization to the earlier of disease progression or death due to any cause. Disease status was assessed at a central laboratory with serum and urine protein electrophoresis, immunofixation, serum-free light chain (SFLC) assay, bone marrow sample evaluation, serum calcium, plasmacytoma evaluation, and skeletal survey. Response and disease progression were determined using a validated computer algorithm based on the International Myeloma Working Group-Uniform Response Criteria (IMWG-URC). Median PFS was derived using the Kaplan-Meier method; participants still alive with no disease progression were censored at the time of their last disease assessment.

    Time frame: From randomization until the data cut-off date of 15 June 2017; median (minimum, maximum) follow-up time for PFS was 12.0 (0, 20) and 12.6 (0, 19) months in each treatment group respectively.

Secondary outcomes

  1. Overall Response Rate

    Disease response was evaluated according to the IMWG-URC using a validated computer algorithm. Overall response rate was defined as the percentage of participants with a best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). sCR: As for CR, normal serum free light chain (SFLC) ratio and no clonal cells in bone marrow (BM). CR: No immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in BM biopsy; VGPR: Serum and urine M-protein detectable by immunofixation but not electrophoresis or ≥ 90% reduction in serum M-protein with urine M-protein \<100 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline. PR: ≥ 50% reduction of serum M-protein and reduction in urine M-protein by ≥ 90% or to \< 200 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline.

    Time frame: Disease response was assessed every 28 days until progressive disease, up to the data cut-off date of 15 June 2017; median time on follow-up was 12.0 and 12.6 months in each treatment group respectively.

  2. Overall Survival

    Overall Survival (OS) was defined as the time from randomization to death due to any cause. Median overall survival was derived using the Kaplan-Meier method; participants still alive were censored at the date last known to be alive.

    Time frame: From randomization until the data cut-off date of 15 June 2017; median (minimum, maximum) follow-up time for OS was 12.6 (0, 20) and 13.2 (0, 19) months in each treatment group respectively.

  3. Number of Participants With Adverse Events (AEs)

    The severity of adverse events was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03, where where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening; Grade 5 = Fatal. Treatment-related adverse events are adverse events considered related to at least 1 investigational product by the investigator, including those with unknown relationship.

    Time frame: From first dose of study drug up to 30 days after last dose, up to the end of study; median (minimum, maximum) duration of treatment was 29.1 (0.1, 156.3) weeks and 38.0 (0.1, 158.3) weeks in each treatment group respectively.

  4. Plasma Carfilzomib Concentration During Cycle 2

    Concentrations of carfilzomib in plasma were measured using a validated assay method. The lower limit of quantification was 0.100 ng/mL.

    Time frame: Cycle 2 day 1 predose, 15 minutes after the start of infusion (once-weekly carfilzomib only), end of infusion, and 30 minutes after the end of infusion

07

Results

Posted Dec 13, 2018

Participant flow

Participants were enrolled from September 2015 to August 2016 at 118 sites in Australia, New Zealand, Japan, North America, and Europe.

Participant flow — Overall Study
MilestoneTwice-weekly Carfilzomib 20/27 mg/m² + DexamethasoneOnce-weekly Carfilzomib 20/70 mg/m² + Dexamethasone
Started238240
Received carfilzomib235238
Completed217227
Not completed2113
Withdrew: Withdrawal by subject1910
Withdrew: Lost to follow-up23

Outcome measures

SecondaryOverall Response Rate

Disease response was evaluated according to the IMWG-URC using a validated computer algorithm. Overall response rate was defined as the percentage of participants with a best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). sCR: As for CR, normal serum free light chain (SFLC) ratio and no clonal cells in bone marrow (BM). CR: No immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in BM biopsy; VGPR: Serum and urine M-protein detectable by immunofixation but not electrophoresis or ≥ 90% reduction in serum M-protein with urine M-protein \<100 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline. PR: ≥ 50% reduction of serum M-protein and reduction in urine M-protein by ≥ 90% or to \< 200 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline.

Time frame:
Disease response was assessed every 28 days until progressive disease, up to the data cut-off date of 15 June 2017; median time on follow-up was 12.0 and 12.6 months in each treatment group respectively.
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participantsTwice-weekly Carfilzomib 20/27 mg/m² + DexamethasoneOnce-weekly Carfilzomib 20/70 mg/m² + Dexamethasone
Overall Response Rate40.8 (34.5 to 47.3)62.9 (56.5 to 69.0)
Statistical analysis
  • Twice-weekly Carfilzomib 20/27 mg/m² + Dexamethasone vs Once-weekly Carfilzomib 20/70 mg/m² + Dexamethasone · Cochran-Mantel-Haenszel · p = < 0.0001 (Progression-free survival, overall response, and overall survival were tested using a fixed sequence hierarchical testing procedure to control the family-wise type I error rate below one-sided 0.025 level.) · Odds ratio (or): 2.485 · 95% CI 1.716 to 3.598Odds ratio (once weekly carfilzomib 20/70 mg/m²/ twice weekly carfilzomib 20/27 mg/m²) was calculated using the Mantel-Haenszel method stratified by the randomization stratification factors.
  • Twice-weekly Carfilzomib 20/27 mg/m² + Dexamethasone vs Once-weekly Carfilzomib 20/70 mg/m² + Dexamethasone · Fisher Exact · p = <0.0001 · Odds ratio (or): 2.466 · 95% CI 1.707 to 3.563Odds ratio (once weekly carfilzomib 20/70 mg/m²/ twice weekly carfilzomib 20/27 mg/m²) was calculated using the Mantel-Haenszel method.
PrimaryProgression Free Survival

Progression-free survival (PFS) was defined as the time from randomization to the earlier of disease progression or death due to any cause. Disease status was assessed at a central laboratory with serum and urine protein electrophoresis, immunofixation, serum-free light chain (SFLC) assay, bone marrow sample evaluation, serum calcium, plasmacytoma evaluation, and skeletal survey. Response and disease progression were determined using a validated computer algorithm based on the International Myeloma Working Group-Uniform Response Criteria (IMWG-URC). Median PFS was derived using the Kaplan-Meier method; participants still alive with no disease progression were censored at the time of their last disease assessment.

Time frame:
From randomization until the data cut-off date of 15 June 2017; median (minimum, maximum) follow-up time for PFS was 12.0 (0, 20) and 12.6 (0, 19) months in each treatment group respectively.
Reported as:
Median · months
Progression Free Survival
monthsTwice-weekly Carfilzomib 20/27 mg/m² + DexamethasoneOnce-weekly Carfilzomib 20/70 mg/m² + Dexamethasone
Progression Free Survival7.6 (5.8 to 9.2)11.2 (8.6 to 13.0)
Statistical analysis
  • Twice-weekly Carfilzomib 20/27 mg/m² + Dexamethasone vs Once-weekly Carfilzomib 20/70 mg/m² + Dexamethasone · Log Rank · p = 0.0014 (Progression-free survival, overall response rate, and overall survival were tested using a fixed sequence hierarchical testing procedure to control the family-wise type I error rate below one-sided 0.025 level.) · Hazard ratio (hr): 0.693 · 95% CI 0.544 to 0.883Hazard ratio (once weekly carfilzomib 20/70 mg/m²/ twice weekly carfilzomib 20/27 mg/m²) was estimated using a Cox proportional hazards model stratified by the randomization stratification factors.
  • Twice-weekly Carfilzomib 20/27 mg/m² + Dexamethasone vs Once-weekly Carfilzomib 20/70 mg/m² + Dexamethasone · Log Rank · p = 0.0033 · Hazard ratio (hr): 0.720 · 95% CI 0.567 to 0.913Hazard ratio (once weekly carfilzomib 20/70 mg/m²/ twice weekly carfilzomib 20/27 mg/m²) was estimated using an unstratified Cox proportional hazards model.
SecondaryOverall Survival

Overall Survival (OS) was defined as the time from randomization to death due to any cause. Median overall survival was derived using the Kaplan-Meier method; participants still alive were censored at the date last known to be alive.

Time frame:
From randomization until the data cut-off date of 15 June 2017; median (minimum, maximum) follow-up time for OS was 12.6 (0, 20) and 13.2 (0, 19) months in each treatment group respectively.
Reported as:
Median · months
Overall Survival
monthsTwice-weekly Carfilzomib 20/27 mg/m² + DexamethasoneOnce-weekly Carfilzomib 20/70 mg/m² + Dexamethasone
Overall SurvivalNA (18.1 to NA)NA (NA to NA)
Statistical analysis
  • Twice-weekly Carfilzomib 20/27 mg/m² + Dexamethasone vs Once-weekly Carfilzomib 20/70 mg/m² + Dexamethasone · Log Rank · p = 0.1070 (Progression-free survival, overall response, and overall survival were tested using a fixed sequence hierarchical testing procedure to control the family-wise type I error rate below one-sided 0.025 level.) · Hazard ratio (hr): 0.800 · 95% CI 0.563 to 1.138Hazard ratio (once weekly carfilzomib 20/70 mg/m²/ twice weekly carfilzomib 20/27 mg/m²) was estimated using a Cox proportional hazards model stratified by the randomization stratification factors.
  • Twice-weekly Carfilzomib 20/27 mg/m² + Dexamethasone vs Once-weekly Carfilzomib 20/70 mg/m² + Dexamethasone · Log Rank · p = 0.1326 · Hazard ratio (hr): 0.820 · 95% CI 0.578 to 1.164Hazard ratio (once weekly carfilzomib 20/70 mg/m²/ twice weekly carfilzomib 20/27 mg/m²) was estimated using an unstratified Cox proportional hazards model.
SecondaryNumber of Participants With Adverse Events (AEs)

The severity of adverse events was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03, where where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening; Grade 5 = Fatal. Treatment-related adverse events are adverse events considered related to at least 1 investigational product by the investigator, including those with unknown relationship.

Time frame:
From first dose of study drug up to 30 days after last dose, up to the end of study; median (minimum, maximum) duration of treatment was 29.1 (0.1, 156.3) weeks and 38.0 (0.1, 158.3) weeks in each treatment group respectively.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsTwice-weekly Carfilzomib 20/27 mg/m² + DexamethasoneOnce-weekly Carfilzomib 20/70 mg/m² + Dexamethasone
Adverse events (AEs)230233
Adverse events Grade ≥ 3152181
Serious adverse events102118
AEs leading to discontinuation of carfilzomib2935
AEs leading to discontinuation of dexamethasone3140
Fatal adverse events2021
Treatment-related adverse events (TRAEs)176180
Treatment-related adverse events Grade ≥ 382108
Serious treatment-related adverse events3157
TRAE leading to discontinuation of carfilzomib1123
TRAEs leading to discontinuation of dexamethasone1329
Fatal treatment-related adverse events35
SecondaryPlasma Carfilzomib Concentration During Cycle 2

Concentrations of carfilzomib in plasma were measured using a validated assay method. The lower limit of quantification was 0.100 ng/mL.

Time frame:
Cycle 2 day 1 predose, 15 minutes after the start of infusion (once-weekly carfilzomib only), end of infusion, and 30 minutes after the end of infusion
Reported as:
Mean · ng/mL
Plasma Carfilzomib Concentration During Cycle 2
ng/mLTwice-weekly Carfilzomib 20/27 mg/m² + DexamethasoneOnce-weekly Carfilzomib 20/70 mg/m² + Dexamethasone
Predose36.2 ± 162203 ± 1380
15 minutes after start of infusion—1370 ± 1410
End of infusion1640 ± 19001130 ± 928
30 minutes after end of infusion104 ± 293480 ± 2300

Adverse events

Collected over All-cause mortality includes deaths that occurred from randomization until the end of study; median (minimum, maximum) follow-up time was 30.7 (0, 39) and 31.2 (0, 38) months in each treatment group respectively. Adverse events are reported from the first dose of study drug up to 30 days after last dose, as of the end of study; median (minimum, maximum) duration of treatment was 29.1 (0.1, 156.3) weeks and 38.0 (0.1, 158.3) weeks in each treatment group respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Twice-weekly Carfilzomib 20/27 mg/m² + Dexamethasone127/238 (53.4%)102/235 (43.4%)204/235 (86.8%)
Once-weekly Carfilzomib 20/70 mg/m² + Dexamethasone119/240 (49.6%)118/238 (49.6%)217/238 (91.2%)
Most frequent serious events
Showing 10 of 159
Most frequent serious events
EventTwice-weekly Carfilzomib 20/27 mg/m² + DexamethasoneOnce-weekly Carfilzomib 20/70 mg/m² + Dexamethasone
PneumoniaInfections and infestations22/23523/238
Acute kidney injuryRenal and urinary disorders8/23512/238
AnaemiaBlood and lymphatic system disorders8/2354/238
Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)7/2354/238
SepsisInfections and infestations3/2356/238
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/2356/238
PyrexiaGeneral disorders5/2354/238
Septic shockInfections and infestations2/2355/238
BronchitisInfections and infestations4/2351/238
Upper respiratory tract infectionInfections and infestations4/2351/238
Most frequent other events
Showing 10 of 36
Most frequent other events
EventTwice-weekly Carfilzomib 20/27 mg/m² + DexamethasoneOnce-weekly Carfilzomib 20/70 mg/m² + Dexamethasone
AnaemiaBlood and lymphatic system disorders73/23569/238
HypertensionVascular disorders49/23558/238
PyrexiaGeneral disorders38/23555/238
DiarrhoeaGastrointestinal disorders51/23553/238
FatigueGeneral disorders47/23550/238
InsomniaPsychiatric disorders49/23539/238
CoughRespiratory, thoracic and mediastinal disorders33/23544/238
Upper respiratory tract infectionInfections and infestations28/23539/238
NauseaGastrointestinal disorders30/23538/238
Back painMusculoskeletal and connective tissue disorders31/23535/238

Baseline characteristics

The intention-to-treat population consisted of all randomly assigned participants.

Age, Continuous
Age, Continuous(years)Twice-weekly Carfilzomib 20/27 mg/m² + DexamethasoneOnce-weekly Carfilzomib 20/70 mg/m² + DexamethasoneTotal
Median66.0 (35 to 83)66.0 (39 to 85)66.0 (35 to 85)
Age, Customized
Age, Customized(Participants)Twice-weekly Carfilzomib 20/27 mg/m² + DexamethasoneOnce-weekly Carfilzomib 20/70 mg/m² + DexamethasoneTotal
18 - 64 years104104208
65 - 74 years10290192
75 - 84 years324577
≥ 85 years011
Sex: Female, Male
Sex: Female, Male(Participants)Twice-weekly Carfilzomib 20/27 mg/m² + DexamethasoneOnce-weekly Carfilzomib 20/70 mg/m² + DexamethasoneTotal
Female110108218
Male128132260
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Twice-weekly Carfilzomib 20/27 mg/m² + DexamethasoneOnce-weekly Carfilzomib 20/70 mg/m² + DexamethasoneTotal
Hispanic or Latino527
Not Hispanic or Latino226235461
Unknown or Not Reported7310
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Twice-weekly Carfilzomib 20/27 mg/m² + DexamethasoneOnce-weekly Carfilzomib 20/70 mg/m² + DexamethasoneTotal
Asian153045
Black or African American235
White202200402
Other9413
Missing10313
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Twice-weekly Carfilzomib 20/27 mg/m² + DexamethasoneOnce-weekly Carfilzomib 20/70 mg/m² + DexamethasoneTotal
0 (Fully active)118118236
1 (Restrictive but ambulatory)120121241
2 (Ambulatory but unable to work)011
Stratification Factor: International Staging System (ISS) stage
Stratification Factor: International Staging System (ISS) stage(Participants)Twice-weekly Carfilzomib 20/27 mg/m² + DexamethasoneOnce-weekly Carfilzomib 20/70 mg/m² + DexamethasoneTotal
Stage 1100100200
Stage 2 or 3138140278
Stratification Factor: Refractory to Bortezomib Treatment
Stratification Factor: Refractory to Bortezomib Treatment(Participants)Twice-weekly Carfilzomib 20/27 mg/m² + DexamethasoneOnce-weekly Carfilzomib 20/70 mg/m² + DexamethasoneTotal
Yes8888176
No150152302
08

Study locations

140 sites
  • Research Site
    Scottsdale, Arizona 85259-5499, United States
  • Mayo Clinic
    Scottsdale, Arizona, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Center for Cancer and Blood Disorders
    Bethesda, Maryland, United States
  • Research Site
    Rockville, Maryland 20850, United States
  • Maryland Oncology Hematology, P.A
    Rockville, Maryland, United States
  • Research Site
    Hackensack, New Jersey 07601, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    Pittsburgh, Pennsylvania 15224, United States
  • Research Site
    Tyler, Texas 75701, United States
  • Blood and Cancer Center of East Texas
    Tyler, Texas, United States
  • Research Site
    Darlinghurst, New South Wales 2010, Australia
  • Research Site
    Tweed Heads, New South Wales 2485, Australia
  • Research Site
    Waratah, New South Wales 2298, Australia
  • Research Site
    Box Hill, Victoria 3128, Australia
  • Research Site
    Antwerpen, 2060, Belgium
  • Research Site
    Brugge, 8000, Belgium
  • Research Site
    Brussel, 1090, Belgium
  • Research Site
    Bruxelles, 1200, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Calgary, Alberta T2N 2T9, Canada
  • Research Site
    Kelowna, British Columbia V1Y 5L3, Canada
  • Research Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Research Site
    St. Johns, Newfoundland and Labrador A1B 3V6, Canada
  • Research Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, Quebec H4J 1C5, Canada
  • Research Site
    Quebec, G1J 1Z4, Canada
  • Research Site
    Brno, 625 00, Czechia
  • Research Site
    Hradec Kralove, 500 05, Czechia
  • Research Site
    Olomouc, 775 20, Czechia
  • Research Site
    Ostrava-Poruba, 708 52, Czechia
  • Research Site
    Praha 10, 100 34, Czechia
  • Research Site
    Praha, 128 08, Czechia
  • Research Site
    Aalborg, 9000, Denmark
  • Research Site
    Copenhagen, 2100, Denmark
  • Research Site
    Odense C, 5000, Denmark
  • Research Site
    Vejle, 7100, Denmark
  • Research Site
    Helsinki, 00290, Finland
  • Research Site
    Tampere, 33521, Finland
  • Research Site
    Turku, 20520, Finland
  • Research Site
    Bayonne, 64109, France
  • Research Site
    Brest, 29609, France
  • Research Site
    Dijon, 21000, France
  • Research Site
    Nantes Cedex 1, 44093, France
  • Research Site
    Nimes cedex 09, 30029, France
  • Research Site
    Paris, 75012, France
  • Research Site
    Pierre-Benite cedex, 69495, France
  • Research Site
    Rennes, 35033, France
  • Research Site
    Tours Cedex 1, 37044, France
  • Research Site
    Köln, 50937, Germany
  • Research Site
    Leipzig, 04103, Germany
  • Research Site
    München, 81241, Germany
  • Research Site
    Rostock, 18057, Germany
  • Research Site
    Tubingen, 72076, Germany
  • Research Site
    Athens, 10676, Greece
  • Research Site
    Athens, 11528, Greece
  • Research Site
    Patra, 26504, Greece
  • Research Site
    Budapest, 1097, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Gyula, 5700, Hungary
  • Research Site
    Kaposvar, 7400, Hungary
  • Research Site
    Ancona, 60126, Italy
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Brescia, 25123, Italy
  • Research Site
    Cagliari, 09121, Italy
  • Research Site
    Catania, 95124, Italy
  • Research Site
    Firenze, 50134, Italy
  • Research Site
    Genova, 16132, Italy
  • Research Site
    Napoli, 80131, Italy
  • Research Site
    Pavia, 27100, Italy
  • Research Site
    Piacenza, 29100, Italy
  • Research Site
    Pisa, 56100, Italy
  • Research Site
    Roma, 00161, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Torino, 10126, Italy
  • Research Site
    Toyohashi-shi, Aichi 441-8570, Japan
  • Research Site
    Fukuoka-shi, Fukuoka 812-8582, Japan
  • Research Site
    Ogaki-shi, Gifu 503-8502, Japan
  • Research Site
    Maebashi-shi, Gunma 371-8511, Japan
  • Research Site
    Shibukawa-shi, Gunma 377-8511, Japan
  • Research Site
    Sapporo-shi, Hokkaido 060-8543, Japan
  • Research Site
    Isehara-shi, Kanagawa 259-1193, Japan
  • Research Site
    Kyoto-shi, Kyoto 602-8566, Japan
  • Research Site
    Sendai-shi, Miyagi 980-8574, Japan
  • Research Site
    Okayama-shi, Okayama 701-1192, Japan
  • Research Site
    Suita-shi, Osaka 565-0871, Japan
  • Research Site
    Kawagoe-shi, Saitama 350-8550, Japan
  • Research Site
    Utsunomiya-shi, Tochigi 320-0834, Japan
  • Research Site
    Chuo-ku, Tokyo 104-0045, Japan
  • Research Site
    Koto-ku, Tokyo 135-8550, Japan
  • Research Site
    Shibuya-ku, Tokyo 150-8935, Japan
  • Research Site
    Tachikawa-shi, Tokyo 190-0014, Japan
  • Research Site
    Fukuoka-shi, 811-1395, Japan
  • Research Site
    Nagoya-shi, 467-8602, Japan
  • Research Site
    Niigata-shi, 951-8566, Japan
  • Research Site
    Tokushima-shi, 770-8539, Japan

Showing the first 100 of 140 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang M, Zahlten-Kumeli A, Stewart AK. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018 Jul;19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1. Epub 2018 Jun 1. Erratum In: Lancet Oncol. 2018 Aug;19(8):e382. doi: 10.1016/S1470-2045(18)30492-3. PubMed 29866475 ↗
  • Facon T, Niesvizky R, Mateos MV, Siegel D, Rosenbaum C, Bringhen S, Weisel K, Ho PJ, Ludwig H, Kumar S, Wang K, Obreja M, Yang Z, Klippel Z, Mezzi K, Goldrick A, Tekle C, Dimopoulos MA. Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. Blood Adv. 2020 Nov 10;4(21):5449-5459. doi: 10.1182/bloodadvances.2020001965. PubMed 33166401 ↗
  • Dimopoulos MA, Niesvizky R, Weisel K, Siegel DS, Hajek R, Mateos MV, Cavo M, Huang M, Zahlten-Kumeli A, Moreau P. Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis. Blood Cancer J. 2020 Mar 9;10(3):35. doi: 10.1038/s41408-020-0300-y. PubMed 32152297 ↗
  • Moreau P, Stewart KA, Dimopoulos M, Siegel D, Facon T, Berenson J, Raje N, Berdeja JG, Orlowski RZ, Yang H, Ma H, Klippel Z, Zahlten-Kumeli A, Mezzi K, Iskander K, Mateos MV. Once-weekly (70 mg/m2 ) vs twice-weekly (56 mg/m2 ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials. Cancer Med. 2020 May;9(9):2989-2996. doi: 10.1002/cam4.2945. Epub 2020 Feb 28. PubMed 32108443 ↗
  • Moreau P, Kumar S, Boccia R, Iida S, Goldschmidt H, Cocks K, Trigg A, Zahlten-Kumeli A, Yucel E, Panjabi SS, Dimopoulos M. Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study). Leukemia. 2019 Dec;33(12):2934-2946. doi: 10.1038/s41375-019-0480-2. Epub 2019 May 15. PubMed 31092895 ↗
  • Kumar SK, Majer I, Panjabi S, Medhekar R, Campioni M, Dimopoulos MA. Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States. Expert Rev Hematol. 2020 Jun;13(6):687-696. doi: 10.1080/17474086.2020.1746639. Epub 2020 Apr 6. PubMed 32249621 ↗
  • Dimopoulos MA, Moreau P, Iida S, Huang SY, Takezako N, Chng WJ, Zahlten-Kumeli A, Sersch MA, Li J, Huang M, Lee JH. Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials. Int J Hematol. 2019 Oct;110(4):466-473. doi: 10.1007/s12185-019-02704-z. Epub 2019 Aug 6. PubMed 31388932 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Jun 2017, 21 months.

Results were first posted in Dec 2018, 1 year 5 months after primary completion. A results delay was requested in Jun 2018.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 21 months is below that.

Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2015
First posted
Apr 9, 2015
StartActual
Sep 9, 2015
Primary completionActual
Jun 15, 2017
CompletionActual
Jan 7, 2019
Results delay requested
Jun 8, 2018
Results first posted
Dec 13, 2018
Last update
Sep 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02412878
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Apr 9, 2015
Start date
Sep 9, 2015
Primary completion
Jun 15, 2017
Completion
Jan 7, 2019
Results posted
Dec 13, 2018
Last update
Sep 23, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carfilzomib · Dexamethasone

Start the discussion